Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-27.2
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales1,912million yenYear on year -27.2%Progress 17.9%
Operating profit-719million yen
Ordinary income-700million yen
Net income attributable to owners of the parent-636million yen
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥(28.16)
Financial position at period-end
Total assets11,063million yen
of which net assets 3,211 million yenEquity ratio 29.0%vs. prior year-end -4.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Regional salesRegion Japan / Net Sales for the Current Period 752,454 thousand yen / Net sales in the same period of the previous year 875,987 thousand yen / Year on year against the same period last year Decline in Revenue, Region United States / Net Sales for the Current Period 405,074 thousand yen / Net sales in the same period of the previous year 811,036 thousand yen / Year on year against the same period last year Decline in Revenue, Region Europe / Net Sales for the Current Period 440,753 thousand yen / Net sales in the same period of the previous year 754,894 thousand yen / Year on year against the same period last year Decline in Revenue, Region Asia / Net Sales for the Current Period 314,605 thousand yen / Net sales in the same period of the previous year 184,229 thousand yen / Year on year against the same period last year Revenue growth
Outlook and shareholder returns
Full-year earnings forecast
Net Sales10,680 million yen (YoY +23.2%)
Operating profit256 million yen
Ordinary income250 million yen
Net income180 million yen
Annual Dividend Forecast8 yen → 8 yen（0.0%）
Factors Behind Changes in Business Performance
The main factors behind the decline in sales and operating losses were delays in the start of clinical trials in the United States due to government shutdowns and other factors, delays in the start of full-scale operations in Europe, the challenging market environment in Japan caused by drug loss and other factors, and the downsizing of existing projects. South Korea reported higher sales and operating profit due to progress on existing projects, while Taiwan reported higher sales and operating profit due to the acquisition of new projects.
Disclosure regarding the going concern assumption
None ("There are no applicable matters.")
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Depreciation and amortization31,719 thousand yen
Orders received and order backlogEnd of fiscal year ending March 2026 11,673 million yen / End of first quarter of fiscal year ending March 2027 12,273 million yen / As of 14 August 2026 11,798 million yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End24,740,000 Shares
Treasury Shares at Period-End2,153,569 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 1,912 million yen (YoY -27.2%) |
| Operating profit | -719 million yen |
| Ordinary income | -700 million yen |
| Profit attributable to owners of the parent | -636 million yen |
| Net income per share | ¥(28.16) |
| Equity ratio | End of the current fiscal period 29 / End of previous period 33.1 |
| Total assets | 11,063 million yen |
| Net assets | 3,211 million yen |
| Full-year earnings forecast | Net Sales 10,680 million yen (YoY +23.2%) / Operating profit 256 million yen / Ordinary income 250 million yen / Net income 180 million yen |
| Annual Dividend Forecast | 8 yen → 8 yen（0.0%） |
| Regional sales | Region Japan / Net Sales for the Current Period 752,454 thousand yen / Net sales in the same period of the previous year 875,987 thousand yen / Year on year against the same period last year Decline in Revenue, Region United States / Net Sales for the Current Period 405,074 thousand yen / Net sales in the same period of the previous year 811,036 thousand yen / Year on year against the same period last year Decline in Revenue, Region Europe / Net Sales for the Current Period 440,753 thousand yen / Net sales in the same period of the previous year 754,894 thousand yen / Year on year against the same period last year Decline in Revenue, Region Asia / Net Sales for the Current Period 314,605 thousand yen / Net sales in the same period of the previous year 184,229 thousand yen / Year on year against the same period last year Revenue growth |
| Orders received and order backlog | End of fiscal year ending March 2026 11,673 million yen / End of first quarter of fiscal year ending March 2027 12,273 million yen / As of 14 August 2026 11,798 million yen |
| Depreciation and amortization | 31,719 thousand yen |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters.") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 24,740,000 Shares |
| Treasury Shares at Period-End | 2,153,569 Shares |
| Factors Behind Changes in Business Performance | The main factors behind the decline in sales and operating losses were delays in the start of clinical trials in the United States due to government shutdowns and other factors, delays in the start of full-scale operations in Europe, the challenging market environment in Japan caused by drug loss and other factors, and the downsizing of existing projects. South Korea reported higher sales and operating profit due to progress on existing projects, while Taiwan reported higher sales and operating profit due to the acquisition of new projects. |
Items this document does not state (13)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitImpairment lossBreakdown of extraordinary income (loss)Material subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.While South Korea and Taiwan reported higher sales, the start of clinical trials for multiple projects in the United States was delayed due to government shutdowns and other factors, and full-scale operations in Europe began in or after the second quarter. In Japan, the challenging market environment caused by drug loss and other factors, as well as the downsizing of existing projects, had an impact.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.